Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Clusterin Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Apolipoprotein J, Apo J
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD194034200R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Urine, Cerebrospinal fluid

Sample Requirements

5 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

5–160 ng/ml

Limit of Detection

0.5 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 6.2%

Inter-assay (Run-to-Run)

n = 8; CV = 7.8%

Spiking Recovery

103,20%

Dilution Linearity

99,30%

Crossreactivity

  • bovine Non-detectable
  • cat Non-detectable
  • dog Non-detectable
  • goat Non-detectable
  • hamster Non-detectable
  • horse Non-detectable
  • mouse Non-detectable
  • pig Non-detectable
  • rabbit Non-detectable
  • rat Non-detectable
  • sheep Non-detectable
  • chicken Not tested
  • human Yes
  • monkey Yes (recommended dilution 1:1500)
Summary

Features

  • It is intended for research use only.
  • The total assay time is less than 3.5 hours.
  • The kit measures Clusterin in serum, plasma, cerebrospinal fluid (CSF), urine, cell culture, and cell lysate.
  • Components of the kit are provided ready to use, concentrated or lyophilized.
  • Standard is recombinant protein based.
  • Quality Controls are human serum based. No animal sera are used.

Research topic

Neural tissue markers, Oncology, Others, Renal disease, Sepsis

Summary

Clusterin (Apolippoprotein J; SP-40,40; TRPM-2; SGP-2; pADHC-9; CLJ; T64; GP III; XIP8) is a highly conserved disulfide-linked secreted heterodimeric glycoprotein of 75-80 kDa but truncated forms targeted to the nucleus have also been identified.
The protein is constitutively secreted by a number of cell types including epithelial and neuronal cells and is a major protein in physiological fluids including plasma, milk, urine, cerebrospinal fluid and semen. Due to its wide breath of tissue distribution many diverse physiological functions have been attributed to Clusterin including sperm maturation, membrane recycling, lipid transportation, tissue remodelling, complement inhibition and cell-cell or cell-substratum interactions. Moreover, it was proposed that Clusterin functions as an extracellular chaperon that stabilizes stressed proteins in a folding-competent state, and that the protein is involved in programmed cell death. Another defining prominent function of Clusterin is its induction in many severe physiological disturbances states including kidney degenerative diseases, prostate and vesicle carcinogenesis, ovarian cancer and several neurodegenerative conditions (Alzheimer’s disease).
Recent study demonstrates, that serum Clusterin level increases significantly in diabetic type II patients and in patients with developing coronary heart disease, or myocardial infarction. These data raise the possibility that elevated Clusterin levels in serum may represent a strong indication of vascular damage.
In patients with systemic lupus erythematosus (SLE), reduced serum Clusterin levels correlated inversely with disease activity. Lowered Clusterin levels could be involved in the pathogeneses of SLE on account of decreased protective effects.
Another interesting observation obtained in rat model suggests that measurement of urinary Clusterin levels may be a useful clinical marker for the severity of renal tubular damage. Furthermore, urinary Clusterin may also help to differentiate between tubular and glomerular forms of proteinuria.

Areas of investigation:
Coronary heart diseases, Myocardial infarction, Neurodegenerative diseases, Kidney degenerative disease, Renal tubular damage

Product References (27)

References

  • Aguilar-Mahecha A, Cantin C, O'Connor-McCourt M, Nantel A, Basik M.Development of reverse phase protein microarrays for the validation of clusterin,a mid-abundant blood biomarker. Proteome Sci. 2009 Apr 6;7:15. doi:10.1186/1477-5956-7-15. PubMed PMID: 19348683; PubMed Central PMCID: PMC2672067. See more on PubMed
  • Banfi C, Parolari A, Brioschi M, Barcella S, Loardi C, Centenaro C, AlamanniF, Mussoni L, Tremoli E. Proteomic analysis of plasma from patients undergoingcoronary artery bypass grafting reveals a protease/antiprotease imbalance infavor of the serpin alpha1-antichymotrypsin. J Proteome Res. 2010 May7;9(5):2347-57. doi: 10.1021/pr901079v. PubMed PMID: 20302328. See more on PubMed
  • Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Randomized phase II study of docetaxel and prednisonewith or without OGX-011 in patients with metastatic castration-resistant prostatecancer. J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23. PubMed PMID: 20733135. See more on PubMed
  • Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W,Seymour L, Eisenhauer EA. Phase II trial of OGX-011 in combination with docetaxelin metastatic breast cancer. Clin Cancer Res. 2009 Jan 15;15(2):708-13. doi:10.1158/1078-0432.CCR-08-1159. PubMed PMID: 19147778. See more on PubMed
  • Cubedo J, Padró T, García-Moll X, Pintó X, Cinca J, Badimon L. Proteomicsignature of Apolipoprotein J in the early phase of new-onset myocardialinfarction. J Proteome Res. 2011 Jan 7;10(1):211-20. doi: 10.1021/pr100805h. Epub2010 Nov 17. PubMed PMID: 21043527. See more on PubMed
  • Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A,Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M,Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease revealsneuroinflammatory activation and biomarker candidates. J Proteome Res. 2007Jul;6(7):2833-40. Epub 2007 Jun 7. PubMed PMID: 17552550. See more on PubMed
  • Dukic L, Simundic AM, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I,Diamandis EP. The role of human kallikrein 6, clusterin and adiponectin aspotential blood biomarkers of dementia. Clin Biochem. 2016 Feb;49(3):213-8. doi: 10.1016/j.clinbiochem.2015.10.014. Epub 2015 Oct 26. PubMed PMID: 26515085. See more on PubMed
  • Flehmig G, Scholz M, Klöting N, Fasshauer M, Tönjes A, Stumvoll M, Youn BS,Blüher M. Identification of adipokine clusters related to parameters of fat mass,insulin sensitivity and inflammation. PLoS One. 2014 Jun 26;9(6):e99785. doi:10.1371/journal.pone.0099785. eCollection 2014. PubMed PMID: 24968098; PubMedCentral PMCID: PMC4072672. See more on PubMed
  • García-Rodríguez S, Arias-Santiago S, Perandrés-López R, Orgaz-Molina J,Castellote L, Buendía-Eisman A, Ruiz JC, Naranjo R, Navarro P, Sancho J, Zubiaur M. Decreased plasma levels of clusterin in patients with psoriasis. ActasDermosifiliogr. 2013 Jul-Aug;104(6):497-503. doi: 10.1016/j.ad.2012.11.019. Epub 2013 Mar 21. English, Spanish. PubMed PMID: 23522962. See more on PubMed
  • Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L. Lowerserum clusterin levels in patients with erosive hand osteoarthritis areassociated with more pain. BMC Musculoskelet Disord. 2018 Jul 27;19(1):264. doi: 10.1186/s12891-018-2179-3. PubMed PMID: 30053814; PubMed Central PMCID:PMC6064100. See more on PubMed
  • Kwon HS, Kim TB, Lee YS, Jeong SH, Bae YJ, Moon KA, Bang BR, Moon HB, Cho YS. Clusterin expression level correlates with increased oxidative stress inasthmatics. Ann Allergy Asthma Immunol. 2014 Mar;112(3):217-21. doi:10.1016/j.anai.2013.12.012. Epub 2014 Jan 7. PubMed PMID: 24428970. See more on PubMed
  • Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M. Serum level ofclusterin and its density in men with prostate cancer as novel biomarkersreflecting disease extension. Urology. 2010 Feb;75(2):454-9. doi:10.1016/j.urology.2009.08.029. Epub 2009 Oct 24. PubMed PMID: 19854485. See more on PubMed
  • Nafee AM, Pasha HF, Abd El Aal SM, Mostafa NA. Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential ofviral-related hepatocellular carcinoma. Clin Biochem. 2012 Sep;45(13-14):1070-4. doi: 10.1016/j.clinbiochem.2012.04.024. Epub 2012 May 2. PubMed PMID: 22580393. See more on PubMed
  • Riaz MA, Stammler A, Borgers M, Konrad L. Clusterin signals via ApoER2/VLDLRand induces meiosis of male germ cells. Am J Transl Res. 2017 Mar15;9(3):1266-1276. eCollection 2017. PubMed PMID: 28386352; PubMed Central PMCID:PMC5376017. See more on PubMed
  • Rithidech KN, Honikel L, Milazzo M, Madigan D, Troxell R, Krupp LB. Proteinexpression profiles in pediatric multiple sclerosis: potential biomarkers. MultScler. 2009 Apr;15(4):455-64. doi: 10.1177/1352458508100047. PubMed PMID:19324981. See more on PubMed
  • Rubinow KB, Tang C, Hoofnagle AN, Snyder CN, Amory JK, Heinecke JW, Page ST.Acute sex steroid withdrawal increases cholesterol efflux capacity andHDL-associated clusterin in men. Steroids. 2012 Apr;77(5):454-60. doi:10.1016/j.steroids.2012.01.002. Epub 2012 Jan 15. PubMed PMID: 22266332; PubMedCentral PMCID: PMC3304018. See more on PubMed
  • Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, BerryS, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group.Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel ormitoxantrone as second-line therapy in patients with metastaticcastrate-resistant prostate cancer progressing after first-line docetaxel: CUOGtrial P-06c. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi:10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25. PubMed PMID: 21788353. See more on PubMed
  • Schlatzer D, Maahs DM, Chance MR, Dazard JE, Li X, Hazlett F, Rewers M,Snell-Bergeon JK. Novel urinary protein biomarkers predicting the development of microalbuminuria and renal function decline in type 1 diabetes. Diabetes Care.2012 Mar;35(3):549-55. doi: 10.2337/dc11-1491. Epub 2012 Jan 11. PubMed PMID:22238279; PubMed Central PMCID: PMC3322681. See more on PubMed
  • Seferovic MD, Chen S, Pinto DM, Gupta MB. Altered liver secretion of vascular regulatory proteins in hypoxic pregnancies stimulate angiogenesis in vitro. JProteome Res. 2011 Apr 1;10(4):1495-504. doi: 10.1021/pr100879z. Epub 2011 Mar10. PubMed PMID: 21319863. See more on PubMed
  • Solichova P, Karpisek M, Ochmanova R, Hanulova Z, Humenanska V, Stejskal D,Bartek J. Urinary clusterin concentrations--a possible marker of nephropathy?Pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007Dec;151(2):233-6. PubMed PMID: 18345256. See more on PubMed
  • Stejskal D, Fiala RR. Evaluation of serum and urine clusterin as a potentialtumor marker for urinary bladder cancer. Neoplasma. 2006;53(4):343-6. PubMedPMID: 16830064. See more on PubMed
  • Stejskal D, Lacnak B, Karpisek M, Kaminek M. Our experiences with measurement of new potential biomarkers in the diagnosis of latent forms of myocardialischemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006Nov;150(2):239-44. PubMed PMID: 17426785. See more on PubMed
  • Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, WahlundLO, Westman E, Kinsey A, Güntert A, Proitsi P, Powell J, Causevic M, Killick R,Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG,Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S. Association of plasma clusterinconcentration with severity, pathology, and progression in Alzheimer disease.Arch Gen Psychiatry. 2010 Jul;67(7):739-48. doi:10.1001/archgenpsychiatry.2010.78. PubMed PMID: 20603455; PubMed Central PMCID:PMC3111021. See more on PubMed
  • Vareka I, Stejskal D, Varekova R, Burianova K, Hnatek J. Changes in clusterin serum concentration levels in oncologic patients during the course of spatherapy--a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009Jun;153(2):117-20. PubMed PMID: 19771135. See more on PubMed
  • Wang Y, Liu YH, Mai SJ, He LJ, Liao YJ, Deng HX, Guan XY, Zeng YX, Kung HF,Xie D. Evaluation of serum clusterin as a surveillance tool for humanhepatocellular carcinoma with hepatitis B virus related cirrhosis. JGastroenterol Hepatol. 2010 Jun;25(6):1123-8. doi:10.1111/j.1440-1746.2009.06205.x. PubMed PMID: 20594228. See more on PubMed
  • Zhang F, Sha J, Wood TG, Galindo CL, Garner HR, Burkart MF, Suarez G, SierraJC, Agar SL, Peterson JW, Chopra AK. Alteration in the activation state of newinflammation-associated targets by phospholipase A2-activating protein (PLAA).Cell Signal. 2008 May;20(5):844-61. doi: 10.1016/j.cellsig.2008.01.004. Epub 2008Jan 17. PubMed PMID: 18291623; PubMed Central PMCID: PMC2729133. See more on PubMed
  • Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW, Chopra AK. PhospholipaseA2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell Signal. 2009 Jul;21(7):1085-99. doi: 10.1016/j.cellsig.2009.02.018. Epub2009 Mar 1. PubMed PMID: 19258036. See more on PubMed
Summary References (13)

References to Clusterin

  • Choi-Miura NH, Oda T: Relationship between multifunctional protein Clusterin and Alzheimer disease. Neurobiol. Aging 1996; 17(5): 717–722
  • Newkirk MM, Apostolakos P, Neville C and Fortin PR: Systemic lupus erythematosus, a disease associated with low levels of Clusterin/ApoJ, and anti-inflammatory protein. J. Rheumatol.1999; 3:597–603
  • Morrissey C, Lakins J, Moquin A, Hussain M, Tenniswood M: An antigen capture assay for the measurement of serum Clusterin concentrations. J. Biochen. Biophys. Methods 2001; 48:13–21
  • Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, Gonos ES: Serum levels of the senescence biomarker Clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Ex. Gerontology 2002; 37: 1175–1187
  • Jones SE, Jomary C: Molecules in focus Clusterin. The International J. of Bioch. & Cell Biol. 2002; 34:427–431
  • Hidaka S, Kränzlin B, Gretz N, Witzgall R: Urinary Clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res. 2002; 310:289–296
  • Chen X, Halberg RB, Ehrhardt WM, Torrealba J and Dove WF: Clusterin as a biomarker in murine and human intestinal neoplasia. PNAS 2003; 100:9530–9535
  • Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y, Wu M, Qian XH and Zhao XH: Loss of Clusterin both in serum and tissue correlates with the tumorogenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003; 9:650–654
  • Wang L, Erling P, Bengtsson AA, Truedsson L, Sturfelt G, Erlinge D: Transcriptional down-regulation of the platelet ADP receptory P2Y12 and Clusterin in patients with systemic lupus erythematosus. J. of Thromb. And Haemost. 2004; 2:1436–1442
  • Patel NV, Wei M, Wong A, Finch CE, Morgan TE: Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neuroscience Letters 2004; 371:199–204
  • Kim BM, Kim SY, Lee S, Shin YJ, Min BH, Bendayan M, Park IS: Clusterin induces differentiation of pancreatic duct calls into insulin-secreting cells. Diabetologia 2006; 49:311–320
  • Kruger S, Mahnken A, Kausch I, Feller AC: Value of Clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006; 67:105–109
  • Stejskal D, Fiala R: Evaluation of serum and urine Clusterin as a potential tumor marker for urinary bladder cancer. Neoplasma 2006; 53:343–34
Related Products Docs